Vascular calcification is increasingly afflicting the aging population, driven by the dysmetabolic milieus of diabetes, chronic kidney disease (CKD), and arterial stiffness. 1-4 Although it has always been considered as an independent predictive factor of cardiovascular events and associated morbidity, the precise relationship between aging and vascular calcification is not well understood. Aging has been demonstrated as a complex multifactorial process, converse to the previous models built on single factors. 5 Therefore, we focused on carnosine (β-alanyl-l-histidine), a naturally occurring dipeptide that is abundant in the brain tissue and muscles. 6 It performs multiple biological functions, including anti-inflammation, anti-oxidation, chelating metal ions, and anti-glycosylation. 6-8 As previously mentioned, the complexity of the aging process has superseded previous constructs based on single factors. Recent reports show that carnosine may improve the treatment outcome of aging-related diseases, such as atherosclerosis, type 2 diabetes, and Alzheimer's disease. 9-11 Studies show that carnosine suppresses cell senescence in cultured human fibroblasts 12 and delays aging in senescence-accelerated mice and drosophila. 13-15 In addition, some in vitro/in vivo studies using human and animal models show that synthesis of carnosine decreases with age. 15 Recent research reports that carnosine can alleviate aging-related vascular diseases, such as atherosclerosis and type 2 diabetes. Vascular calcification is a complication that also occurs during aging,